Katherine Fuh

Medicine & Life Sciences

1. Ovarian Neoplasms 100%
2. Endometrial Neoplasms 72%
3. Survival 40%
4. Neoplasms 37%
5. Uterine Neoplasms 31%
6. Heterografts 29%
7. Neoplasm Metastasis 29%
8. Cancer Survivors 22%
9. Ovarian Epithelial Carcinoma 21%
10. Receptor Protein-Tyrosine Kinases 20%
11. Radiotherapy 20%
12. Cardiogenic Shock 19%
13. Hemodynamics 18%
14. Randomized Controlled Trials 18%
15. Text Messaging 18%
16. Vasoconstriction 17%
17. Shock 17%
18. Weight Loss 17%
19. Mesenteric Ischemia 16%
20. Drug Therapy 16%
21. Homologous Recombination 15%
22. Paclitaxel 15%
23. Poly(ADP-ribose) Polymerase Inhibitors 14%
24. Obesity 14%
25. Platinum 13%
26. Renal Cell Carcinoma 13%
27. Recurrence 12%
28. Therapeutics 12%
29. Radiation 12%
30. Hemorrhagic Shock 12%
31. Angiotensins 12%
32. R428 compound 12%
33. Discoidin Domain Receptor 2 12%
34. Recombinational DNA Repair 12%
35. Proteogenomics 11%
36. entinostat 11%
37. Lymph Node Excision 11%
38. Renin 10%
39. isosorbide-5-mononitrate 10%
40. olaparib 10%
41. DNA Repair-Deficiency Disorders 10%
42. Percutaneous Nephrostomy 10%
43. Weights and Measures 10%
44. Vulvar Neoplasms 9%
45. Histology 9%
46. Counseling 9%
47. Perfusion 9%
48. Chorioamnionitis 9%
49. Hospice Care 9%
50. Misoprostol 9%